StockNews.AI
SRDX
StockNews.AI
11 days

Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance

1. SRDX reported a 3% year-over-year revenue decline at $29.6 million. 2. The company has updated its financial guidance for FY ending September 2025.

+1.14%Current Return
VS
+0.78%S&P 500
$35.0108/08 07:07 AM EDTEvent Start

$35.4108/11 07:18 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bearish?

A 3% revenue decline is concerning, reflecting potential ongoing challenges. Historical examples show that consistent revenue declines often lead to negative stock market performance.

How important is it?

The revenue decline and updated guidance indicate current trouble, which investors may take seriously. Earnings reports are critical for stock sentiment and price movements.

Why Short Term?

Immediate effects will likely reflect in the stock price due to current earnings report. Swift market reactions often occur after disappointing quarterly results.

Related Companies

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”).

Related News